Lindsay Shea is director of the Policy and Analytics Center at the A.J. Drexel Autism Institute at Drexel University in Philadelphia, Pennsylvania. She is also interim leader of the institute’s Life Course Outcomes Research Program. She focuses on research that is conducted in partnership with and that directly impacts communities and policymakers.
Lindsay Shea
Director, Policy and Analytics Center
A.J. Drexel Autism Institute
From this contributor
Pitfalls in using autism claims data: Q&A with Lindsay Shea
Insurance claims data are useful for autism research, but the field needs to standardize how they are mined, Shea says.
Pitfalls in using autism claims data: Q&A with Lindsay Shea
By
Anna Goshua
14 December 2021 | 6 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read